The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Bristol-Myers Squibb's revenues will contract -8.8% and EPS will decrease -8.3%.
The average estimate for revenue is $4.05 billion. On the bottom line, the average EPS estimate is $0.44.
Last quarter, Bristol-Myers Squibb reported revenue of $3.83 billion. GAAP reported sales were 27% lower than the prior-year quarter's $5.25 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.41. GAAP EPS of $0.37 for Q1 were 42% lower than the prior-year quarter's $0.64 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 72.6%, 260 basis points worse than the prior-year quarter. Operating margin was 17.5%, much worse than the prior-year quarter. Net margin was 15.9%, 510 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $16.36 billion. The average EPS estimate is $1.80.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,661 members out of 1,775 rating the stock outperform, and 114 members rating it underperform. Among 482 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 464 give Bristol-Myers Squibb a green thumbs-up, and 18 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bristol-Myers Squibb is outperform, with an average price target of $35.91.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Bristol-Myers Squibb. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Bristol-Myers Squibb to My Watchlist.